FDA grants FX-322 fast track designation

Frequency Therapeutics

10 October 2019 - The company also announced today that the U.S. FDA has granted fast track designation for FX-322. 

At present, there are no FDA approved medicines for sensorineural hearing loss. In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.

Read Frequency Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Cellular therapy , Fast track